185750.KS
Chong Kun Dang Pharmaceutical Corp. [185750.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
185750.KS Stock Summary
Top 185750.KS Correlated Resources
185750.KS
Top 10 Correlated Stocks
185750.KS
In the News
185750.KS Financial details
Company Rating
Strong Buy
Market Cap
1004.05B
Income
70.69B
Revenue
1453.16B
Book val./share
19493.01
Cash/share
-
Dividend
-
Dividend %
-
Employees
2.34K
Optionable
No
Shortable
Yes
Earnings
08 Feb 2023
P/E
36.63
Forward P/E
-
PEG
-4.99
P/S
1.78
P/B
4.23
P/C
-
P/FCF
-81.33
Quick Ratio
-
Current Ratio
1.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
2.25K
EPS next Y
-
EPS next Q
-
EPS this Y
-95.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-38.71%
Revenue last 5Y
8.72%
Revenue Q/Q
4.88%
EPS Q/Q
23.28%
-
-
-
-
SMA20
-1.52%
SMA50
-5.99%
SMA100
-2.79%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
12%
ROC
0.13%
Gross Margin
36%
Oper. Margin
7%
Profit Margin
5%
Payout
-
Shs Outstand
12.2M
Shs Float
7.36M
-
-
-
-
Target Price
-
52W Range
69523.81-99047.62
52W High
-16.81%
52W Low
+18.52%
RSI
46.24
Rel Volume
0.82
Avg Volume
16.27K
Volume
13.33K
Perf Week
-0.48%
Perf Month
-6.58%
Perf Quarter
-10.34%
Perf Half Y
-7.1%
-
-
-
-
Beta
1.09707
-
-
Volatility
524.89%, 2750.36%
Prev Close
-0.48%
Price
82400
Change
0.61%
185750.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 77.37K | 88.24K | 99.72K | 120.46K | 12.81K | |
| Net income per share | 4.71K | 3.91K | 4.98K | 8.47K | 407.25 | |
| Operating cash flow per share | 7.15K | 3.93K | 7.14K | 9.64K | 123.01 | |
| Free cash flow per share | 5.28K | 1.66K | 4.84K | 6.24K | -371.22 | |
| Cash per share | 3.98K | 4.24K | 8.53K | 14.96K | 1.79K | |
| Book value per share | 35.14K | 39.56K | 43.75K | 50.98K | 5.4K | |
| Tangible book value per share | 34.03K | 38.34K | 42.41K | 49.23K | 5.2K | |
| Share holders equity per share | 35.14K | 39.56K | 43.75K | 50.98K | 5.4K | |
| Interest debt per share | 9.27K | 9.89K | 11.2K | 12.94K | 2.3K | |
| Market cap | 1356.82B | 1011.03B | 922.8B | 1890.43B | 9682.18B | |
| Enterprise value | 1413.81B | 1069.56B | 963.94B | 1902.91B | 9787.42B | |
| P/E ratio | 25.22 | 23.85 | 17.13 | 20.63 | 226.64 | |
| Price to sales ratio | 1.53 | 1.06 | 0.85 | 1.45 | 7.21 | |
| POCF ratio | 16.61 | 23.72 | 11.94 | 18.12 | 750.33 | |
| PFCF ratio | 22.48 | 56.21 | 17.6 | 28 | -248.64 | |
| P/B Ratio | 3.38 | 2.36 | 1.95 | 3.43 | 17.11 | |
| PTB ratio | 3.38 | 2.36 | 1.95 | 3.43 | 17.11 | |
| EV to sales | 1.6 | 1.12 | 0.89 | 1.46 | 7.28 | |
| Enterprise value over EBITDA | 14.11 | 11.5 | 9.74 | 12.63 | 87.02 | |
| EV to operating cash flow | 17.31 | 25.09 | 12.47 | 18.24 | 758.49 | |
| EV to free cash flow | 23.43 | 59.46 | 18.39 | 28.19 | -251.34 | |
| Earnings yield | 0.04 | 0.04 | 0.06 | 0.05 | 0 | |
| Free cash flow yield | 0.04 | 0.02 | 0.06 | 0.04 | 0 | |
| Debt to equity | 0.05 | 0.11 | 0.05 | 0.1 | 0.24 | |
| Debt to assets | 0.4 | 0.39 | 0.41 | 0.42 | 0.46 | |
| Net debt to EBITDA | 0.57 | 0.63 | 0.42 | 0.08 | 0.94 | |
| Current ratio | 1.64 | 1.91 | 1.7 | 1.87 | 2.08 | |
| Interest coverage | 22.16 | 27.93 | 23.67 | 32.02 | 23.51 | |
| Income quality | 1.52 | 1.01 | 1.43 | 1.14 | 0.3 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Payout ratio | 0.16 | 0.2 | 0.16 | 0.1 | 0.25 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.08 | 0.09 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.26 | -0.58 | -0.32 | -0.35 | -4.02 | |
| Capex to revenue | -0.02 | -0.03 | -0.02 | -0.03 | -0.04 | |
| Capex to depreciation | -0.97 | -1.16 | -1.08 | -1.55 | -1.89 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 61.01K | 59.01K | 70K | 98.57K | 7.03K | |
| ROIC | 0.17 | 0.15 | 0.14 | 0.2 | 0.13 | |
| Return on tangible assets | 0.08 | 0.06 | 0.07 | 0.1 | 0.04 | |
| Graham Net | -15.42K | -15.77K | -14.76K | -12.95K | -1.73K | |
| Working capital | 142.86B | 185.82B | 194.07B | 279.49B | 346.92B | |
| Tangible asset value | 388.96B | 415.52B | 459.04B | 532.56B | 545B | |
| Net current asset value | 92.99B | 109.74B | 144.74B | 205.37B | 186.26B | |
| Invested capital | 0.26 | 0.24 | 0.25 | 0.25 | 0.42 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 107.65B | 106.36B | 123.04B | 144.12B | 136.72B | |
| Average inventory | 144.95B | 156.58B | 167.01B | 185.57B | 205.14B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 49.52 | 43.48 | 55.13 | 64.63 | 55.68 | |
| Days of inventory on hand | 72.58 | 80.88 | 80.27 | 83.22 | 96.76 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 7.37 | 8.39 | 6.62 | 5.65 | 6.55 | |
| Inventory turnover | 5.03 | 4.51 | 4.55 | 4.39 | 3.77 | |
| ROE | 0.13 | 0.1 | 0.11 | 0.17 | 0.08 | |
| Capex per share | -1.87K | -2.27K | -2.3K | -3.4K | -494.23 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 30.32K | 11.52K | 10.86K | 11.65K | 12.22K | |
| Net income per share | 190 | 49.9 | 554.55 | 736.91 | 908.45 | |
| Operating cash flow per share | 921.96 | -816.81 | 204.96 | 888.89 | 108.66 | |
| Free cash flow per share | -77.37 | -1.22K | -155.66 | 615.82 | -251.04 | |
| Cash per share | 20.47K | 5.96K | 0 | 0 | 0 | |
| Book value per share | 50.34K | 18.01K | 18K | 18.59K | 19.49K | |
| Tangible book value per share | 48.51K | 17.35K | 18K | 18.57K | 19.46K | |
| Share holders equity per share | 50.34K | 18.01K | 18K | 18.59K | 19.49K | |
| Interest debt per share | 21.14K | 7.59K | -20.25 | -77.98 | -62.14 | |
| Market cap | 1295.53B | 3487.73B | 3091.83B | 2749.34B | 2469.69B | |
| Enterprise value | 1309.78B | 3592.97B | 3091.83B | 2749.34B | 2469.69B | |
| P/E ratio | 151 | 556.06 | 44.36 | 29.68 | 21.63 | |
| Price to sales ratio | 3.79 | 9.64 | 9.06 | 7.51 | 6.43 | |
| POCF ratio | 124.48 | -135.89 | 480.09 | 98.44 | 723.35 | |
| PFCF ratio | -1.48K | -90.81 | -632.14 | 142.09 | -313.1 | |
| P/B Ratio | 2.28 | 6.16 | 5.47 | 4.71 | 4.03 | |
| PTB ratio | 2.28 | 6.16 | 5.47 | 4.71 | 4.03 | |
| EV to sales | 3.83 | 9.93 | 9.06 | 7.51 | 6.43 | |
| Enterprise value over EBITDA | 39.69 | 300.27 | 98.83 | 123.69 | 70.25 | |
| EV to operating cash flow | 125.84 | -139.99 | 480.09 | 98.44 | 723.35 | |
| EV to free cash flow | -1.5K | -93.55 | -632.14 | 142.09 | -313.1 | |
| Earnings yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | -0.01 | 0 | 0.01 | 0 | |
| Debt to equity | 0.26 | 0.24 | 0 | 0 | 0 | |
| Debt to assets | 0.48 | 0.46 | 0.47 | 0.47 | 0.45 | |
| Net debt to EBITDA | 0.43 | 8.8 | 0 | 0 | 0 | |
| Current ratio | 2.07 | 2.08 | 1.99 | 1.87 | 1.94 | |
| Interest coverage | 34.07 | 3.41 | -39.37 | -11 | -20.14 | |
| Income quality | 4.85 | -16.37 | 0.37 | 1.21 | 0.12 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.29 | 0.29 | 0.26 | |
| Research and developement to revenue | 0.1 | 0.14 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0 | 0 | 0 | |
| Capex to operating cash flow | -1.08 | 0.5 | -1.76 | -0.31 | -3.31 | |
| Capex to revenue | -0.03 | -0.04 | -0.03 | -0.02 | -0.03 | |
| Capex to depreciation | -1.64 | -1.72 | -1.41 | -1.02 | -1.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 14.67K | 4.5K | 14.99K | 17.56K | 19.96K | |
| ROIC | 0.05 | 0.01 | 0.03 | 0.04 | 0.05 | |
| Return on tangible assets | 0 | 0 | 0.02 | 0.02 | 0.03 | |
| Graham Net | -15.08K | -5.77K | -16.01K | -16.35K | -15.88K | |
| Working capital | 366.97B | 346.92B | 340.98B | 329.11B | 343.76B | |
| Tangible asset value | 547.6B | 545B | 0 | 0 | 0 | |
| Net current asset value | 195.28B | 186.26B | 180.95B | 193.15B | 209.59B | |
| Invested capital | 0.42 | 0.42 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 57.01 | 49.02 | 0 | 0 | 0 | |
| Days of inventory on hand | 94.2 | 85.17 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.58 | 1.84 | 0 | 0 | 0 | |
| Inventory turnover | 0.96 | 1.06 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0.03 | 0.04 | 0.05 | |
| Capex per share | -999.33 | -405.5 | -360.62 | -273.07 | -359.7 |
185750.KS Frequently Asked Questions
What is Chong Kun Dang Pharmaceutical Corp. stock symbol ?
Chong Kun Dang Pharmaceutical Corp. is a KR stock and trading under the symbol 185750.KS
What is Chong Kun Dang Pharmaceutical Corp. stock quote today ?
Chong Kun Dang Pharmaceutical Corp. stock price is $82400 today.
Is Chong Kun Dang Pharmaceutical Corp. stock public?
Yes, Chong Kun Dang Pharmaceutical Corp. is a publicly traded company.
Company Profile
- Volume Average 16.27K
- Market Capitalization 1004.05B
- Employee 2.34K
- CEO Mr. Young-Joo Kim
- Headquarters Seoul,KR
- IPO Date 2013-12-06
-
Website
https://www.ckdpharm.com 
Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
